Pharmaceutics (Dec 2022)

Potential of [<sup>11</sup>C](<i>R</i>)-PK11195 PET Imaging for Evaluating Tumor Inflammation: A Murine Mammary Tumor Model

  • Aline Morais de Souza,
  • Caroline Cristiano Real,
  • Mara de Souza Junqueira,
  • Larissa Estessi de Souza,
  • Fábio Luiz Navarro Marques,
  • Carlos Alberto Buchpiguel,
  • Roger Chammas,
  • Marcelo Tatit Sapienza,
  • Daniele de Paula Faria

DOI
https://doi.org/10.3390/pharmaceutics14122715
Journal volume & issue
Vol. 14, no. 12
p. 2715

Abstract

Read online

Background: Breast tumor inflammation is an immunological process that occurs mainly by mediation of Tumor-Associated Macrophages (TAM). Aiming for a specific measurement of tumor inflammation, the current study evaluated the potential of Positron Emission Tomography (PET) imaging with [11C](R)-PK11195 to evaluate tumor inflammation in a mammary tumor animal model. Methods: Female Balb/C mice were inoculated with 4T1 cells. The PET imaging with [11C](R)-PK11195 and [18F]FDG was acquired 3 days, 1 week, and 2 weeks after cell inoculation. Results: The [11C](R)-PK11195 tumor uptake increased from 3 days to 1 week, and decreased at 2 weeks after cell inoculation, as opposed to the [18F]FDG uptake, which showed a slight decrease in uptake at 1 week and increased uptake at 2 weeks. In the control group, no significant differences occurred in tracer uptake over time. Tumor uptake of both radiopharmaceuticals is more expressed in tumor edge regions, with greater intensity at 2 weeks, as demonstrated by [11C](R)-PK11195 autoradiography and immunofluorescence with TSPO antibodies and CD86 pro-inflammatory phenotype. Conclusion: The [11C](R)-PK11195 was able to identify heterogeneous tumor inflammation in a murine model of breast cancer and the uptake varied according to tumor size. Together with the glycolytic marker [18F]FDG, molecular imaging with [11C](R)-PK11195 may provide a better characterization of inflammatory responses in cancer.

Keywords